retatrutide dose study What caught my attention wasn't just the number. It was what the number represents. New Phase 3 trial data for showed an average weight loss of 28.3% at the highest Retatrutide microdosing: guide to split

Telehealth provides medical oversight without the scheduling challenges of traditional in-person care

If the FDA escalates enforcement against compounding pharmacies or telehealth platforms offering broadly compounded tirzepatide, your supply could be interrupted with little warning

Alternatives to retatrutide While retatrutide is still in trials, there are other medications already approved by the FDA for treating both type 2 diabetes and obesity/overweight

FDA approval in 2019 (under the brand name Vyleesi) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women

Watch TV, scroll your phone, or take a nap, whatever feels good

Cardiovascular and non- cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta- analysis of randomized controlled cardiovascular outcome trials